NOS inhibitors may act to reverse the negative pathophysiological effects of NO overproduction on vascular tone and the hyporeactivity to vasopressor agents during sepsis [16, 17]. In the clinical trial setting, the principal agents that have been used in sepsis for this purpose are non-selective NOS inhibitors, such as methylarginine (L-NMMA) and nitroarginine (L-NNA). This evidence concerns the gene NOS2 and Sepsis.